Common goal areas in the treatment of upper limb spasticity: a multicentre analysis

Abstract

Objective:

We aimed to develop a goal classification of individualised goals for spasticity treatment incorporating botulinum toxin intervention for upper limb spasticity to under-pin a more structured approach to future goal setting.

Design:

Individualised goals for spasticity treatment incorporating botulinum toxin intervention for upper limb spasticity (n=696) were analysed initially from four studies published in 2008-2012, spanning a total of 18 centres (12 in the UK and 6 in Australia). Goals were categorised and mapped onto the closest matching domains of the WHO International Classification of Functioning. Confirmatory analysis included a further 927 goals from a large international cohort study spanning 22 countries published in 2013.

Results:

Goal categories could be assigned into two domains, each subdivided into three key goal areas: Domain 1: symptoms/impairment n=322 (46%): a. pain/discomfort n=78 (11%), b. involuntary movements n=75 (11%), c. range of movement/contracture prevention n=162 (23%). Domain 2: Activities/function n=374 (54%): a. passive function (ease of caring for the affected limb) n=242 (35%), b active function (using the affected limb in active tasks) n=84 (12%), c. mobility n=11 (2%).

Over 99% of the goals from the large international cohort fell into the same six areas, confirming the international applicability of the classification.

Conclusions:

Goals for management of upper limb spasticity, in worldwide clinical practice, fall into six main goal areas.

Keywords

Goal-setting activities arm muscle spasticity botulinum toxin

Get full access to this article

View all access options for this article.

References

Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy and Association of Chartered Physiotherapist Interested in Neurology. Spasticity in adults: management using botulinum toxin - National Guidelines. London: Royal College of Physicians, Clinical Effectiveness and Evaluation Unit, 2009.

Ashford

Turner-Stokes

. Goal attainment for spasticity management using botulinum toxin. Physiotherapy Research International 2006; 11: 24–34.

McCrory

Turner-Stokes

Baguley

. Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centered outcomes. Journal of Rehabilitation Medicine 2009; 41: 536–544.

Turner-Stokes

Baguley

De Graaff

. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: A secondary analysis from a double-blind placebo-controlled randomised clinical trial. Journal of Rehabilitation Medicine 2010; 42: 81–89.

Borg

Ward

Wissel

. Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: Evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. Journal of Rehabilitation Medicine 2011; 43: 15–22.

Turner-Stokes

Fheodoroff

Jacinto

Maisonobe

. Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open. 2013; doi:10.1136/bmjopen-2013–002771

Turner-Stokes

Fheodoroff

Jacinto

Maisonobe

Zakine

. Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. BMJ Open 2013; 3: e002230.

Tennant

. Goal attainment scaling: Current methodological challenges. Disability and Rehabilitation 2007; 29: 1583–1588.

Turner-Stokes

Williams

Ashford

. A UK pilot for a large international prospective cohort analysis of the use of Botulinum Toxin A (BoNT-A) in upper limb spasticity. Physical Medicine & Rehabilitation 2012; 2: S190-S199.

10.

Ashford

Turner-Stokes

. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes. Disability and Rehabilitation 2009; 31: 220–226.

11.

Turner-Stokes

. Goal attainment scaling (GAS) a practical guide. Clinical Rehabilitation 2009; 23: 362–370.

12.

Kiresuk

Sherman

. Goal attainment scaling: a general method of evaluating comprehensive mental health programmes. Community Mental Health Journal 1968; 4: 443–453.

13.

WHO. International Classification of Functioning, Disability and Health. Geneva: World Health Organisation, 2002.

14.

Sheean

. Botulinum treatment of spasticity: Why is it difficult to show a functional benefit? Trauma and Rehabilitation 2001: 771–776.

15.

Jackson

Horn

Kersten

Turner-Stokes

. Development of a pictorial scale of pain intensity for patients with communication impairments: initial validation in a general population Clinical Medicine 2006; 6: 580–585.

16.

MacFarlane

Turner-Stokes

De Souza

. The associated reaction rating scale: a clinical tool to measure associated reactions in the hemiplegic upper limb. Clinical Rehabilitation 2002; 16: 726–735.

17.

Ashford

Slade

Nair

Turner-Stokes

. Arm Activity measure (ArmA) application for recording functional gain following focal spasticity treatment. International Journal of Therapy and Rehabilitation 2014; 21: 10–17.

18.

Ashford

Slade

Turner-Stokes

. Conceptualisation and development of the Arm Activity measure (ArmA) for assessment of activity in the hemiparetic arm. Disability and Rehabilitation 2013; 18 1513–1518.

19.

Ashford

Slade

Turner-Stokes

. Initial psychometric evaluation of the Arm Activity Measure (ArmA): a measure of activity in the hemiparetic arm. Clinical Rehabilitation 2013; 27: 728–740.